A Phase I Clinical Study to evaluate the safety, pharmacokinetics and anti-tumor activity of NRC-2694-A in patients with advanced Solid Malignancies
Latest Information Update: 07 Jul 2020
Price :
$35 *
At a glance
- Drugs NRC 2694A (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Natco Pharma
- 30 Jun 2020 Status changed from not yet recruiting to completed.
- 25 Jan 2014 Planned End Date changed to 13 Jan 2016.
- 25 Jan 2014 New trial record